Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BTMD NASDAQ:CRBP NYSE:CYBN NASDAQ:MRSN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTMDbiote$2.98-0.7%$3.34$2.76▼$6.98$147.33M1.16128,237 shs68,683 shsCRBPCorbus Pharmaceuticals$14.83+14.0%$10.21$4.64▼$20.77$181.74M2.84153,442 shs284,701 shsCYBNCybin$6.08-2.1%$6.76$4.81▼$13.88$156.42M0.63381,902 shs823,100 shsMRSNMersana Therapeutics$8.28+3.5%$7.22$5.21▼$70.75$41.32M0.945,827 shs75,589 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTMDbiote0.00%-0.33%-12.09%-29.22%-42.91%CRBPCorbus Pharmaceuticals0.00%+22.46%+48.00%+94.93%-26.26%CYBNCybin0.00%+3.75%+1.67%-23.76%-31.61%MRSNMersana Therapeutics0.00%+9.38%+16.29%+14.21%-83.76%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTMDbiote$2.98-0.7%$3.34$2.76▼$6.98$147.33M1.16128,237 shs68,683 shsCRBPCorbus Pharmaceuticals$14.83+14.0%$10.21$4.64▼$20.77$181.74M2.84153,442 shs284,701 shsCYBNCybin$6.08-2.1%$6.76$4.81▼$13.88$156.42M0.63381,902 shs823,100 shsMRSNMersana Therapeutics$8.28+3.5%$7.22$5.21▼$70.75$41.32M0.945,827 shs75,589 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTMDbiote0.00%-0.33%-12.09%-29.22%-42.91%CRBPCorbus Pharmaceuticals0.00%+22.46%+48.00%+94.93%-26.26%CYBNCybin0.00%+3.75%+1.67%-23.76%-31.61%MRSNMersana Therapeutics0.00%+9.38%+16.29%+14.21%-83.76%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBTMDbiote 2.33Hold$6.00101.34% UpsideCRBPCorbus Pharmaceuticals 2.90Moderate Buy$45.43206.33% UpsideCYBNCybin 3.25Buy$85.001,298.03% UpsideMRSNMersana Therapeutics 2.71Moderate Buy$56.60583.57% UpsideCurrent Analyst Ratings BreakdownLatest MRSN, CYBN, CRBP, and BTMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/27/2025BTMDbioteWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)9/27/2025CRBPCorbus PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025MRSNMersana TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/17/2025CRBPCorbus PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$40.008/14/2025MRSNMersana TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$250.00 ➝ $36.008/14/2025MRSNMersana TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$125.00 ➝ $30.008/13/2025MRSNMersana TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$17.008/7/2025BTMDbioteB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$8.00 ➝ $4.008/6/2025CRBPCorbus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$56.00 ➝ $53.007/30/2025CRBPCorbus PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy$28.007/12/2025CRBPCorbus PharmaceuticalsLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 10/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBTMDbiote$197.19M0.75$0.77 per share3.89($2.78) per share-1.07CRBPCorbus PharmaceuticalsN/AN/AN/AN/A$11.69 per shareN/ACYBNCybinN/AN/AN/AN/A$10.83 per shareN/AMRSNMersana Therapeutics$40.50M1.02N/AN/A($1.92) per share-4.31Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBTMDbiote$3.16M$0.903.315.52N/A15.73%-21.00%18.26%11/11/2025 (Estimated)CRBPCorbus Pharmaceuticals-$40.21M-$4.76N/AN/AN/AN/A-43.65%-39.62%11/6/2025 (Estimated)CYBNCybin-$57.88M-$4.60N/AN/AN/AN/A-37.58%-36.59%N/AMRSNMersana Therapeutics-$69.19M-$14.62N/AN/AN/A-212.94%N/A-54.85%11/12/2025 (Estimated)Latest MRSN, CYBN, CRBP, and BTMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025MRSNMersana Therapeutics-$3.75-$4.08-$0.33-$4.87$6.06 million$3.06 million8/6/2025Q2 2025BTMDbiote$0.06$0.10+$0.04$0.10$49.52 million$48.86 million8/5/2025Q2 2025CRBPCorbus Pharmaceuticals-$1.55-$1.44+$0.11-$1.44N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBTMDbioteN/AN/AN/AN/AN/ACRBPCorbus PharmaceuticalsN/AN/AN/AN/AN/ACYBNCybinN/AN/AN/AN/AN/AMRSNMersana TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBTMDbioteN/A0.980.74CRBPCorbus PharmaceuticalsN/A9.219.21CYBNCybinN/A24.2424.24MRSNMersana TherapeuticsN/A1.351.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBTMDbiote21.68%CRBPCorbus Pharmaceuticals64.64%CYBNCybin17.94%MRSNMersana Therapeutics93.92%Insider OwnershipCompanyInsider OwnershipBTMDbiote24.00%CRBPCorbus Pharmaceuticals3.60%CYBNCybin15.00%MRSNMersana Therapeutics13.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBTMDbiote19449.44 million37.57 millionNot OptionableCRBPCorbus Pharmaceuticals4012.26 million11.81 millionOptionableCYBNCybin5025.19 million17.96 millionNot OptionableMRSNMersana Therapeutics1504.99 million4.34 millionOptionableMRSN, CYBN, CRBP, and BTMD HeadlinesRecent News About These CompaniesCritical Contrast: Mersana Therapeutics (NASDAQ:MRSN) & Monopar Therapeutics (NASDAQ:MNPR)September 30, 2025 | americanbankingnews.comMartin Jr. Huber Sells 2,012 Shares of Mersana Therapeutics (NASDAQ:MRSN) StockSeptember 16, 2025 | insidertrades.comWall Street Analysts See a 314.81% Upside in Mersana Therapeutics (MRSN): Can the Stock Really Move This High?September 8, 2025 | zacks.comMersana Therapeutics Faces Nasdaq Non-Compliance NoticeSeptember 6, 2025 | msn.comWall Street Analysts Think Mersana Therapeutics (MRSN) Could Surge 248.83%: Read This Before Placing a BetAugust 22, 2025 | zacks.comMersana Therapeutics price target adjusted to $36 at Truist after reverse splitAugust 14, 2025 | msn.comMersana Therapeutics, Inc. (NASDAQ:MRSN) Q2 2025 Earnings Call TranscriptAugust 14, 2025 | insidermonkey.comMersana Therapeutics Reports Q2 2025 Financial ResultsAugust 14, 2025 | msn.comMersana Therapeutics, Inc. (NASDAQ:MRSN) Q2 2025 Earnings Call TranscriptAugust 14, 2025 | msn.comMersana Therapeutics reports Q2 EPS ($4.87), consensus ($4.25)August 13, 2025 | msn.comMersana Therapeutics, Inc. (MRSN) Q2 2025 Earnings Call TranscriptAugust 13, 2025 | seekingalpha.comMersana Therapeutics, Inc.: Mersana Therapeutics Provides Business Update and Announces Second Quarter 2025 Financial ResultsAugust 13, 2025 | finanznachrichten.deMersana Misses Fiscal Q2 Revenue TargetAugust 13, 2025 | theglobeandmail.comMersana Therapeutics Provides Business Update and Announces Second Quarter 2025 Financial ResultsAugust 13, 2025 | finance.yahoo.comMersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Lags Revenue EstimatesAugust 13, 2025 | zacks.comMersana Therapeutics Provides Business Update and Announces Second Quarter 2025 Financial ResultsAugust 13, 2025 | globenewswire.comMersana Therapeutics Q2 2025 Earnings PreviewAugust 12, 2025 | msn.comA Look at Mersana Therapeutics's Upcoming Earnings ReportAugust 12, 2025 | benzinga.comEarnings To Watch: Mersana Therapeutics Inc (MRSN) Reports Q2 2025 ResultAugust 12, 2025 | finance.yahoo.comMersana Therapeutics to Host Second Quarter 2025 Conference Call on August 13, 2025August 6, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMRSN, CYBN, CRBP, and BTMD Company Descriptionsbiote NASDAQ:BTMD$2.98 -0.02 (-0.67%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$3.05 +0.07 (+2.35%) As of 10/3/2025 05:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.Corbus Pharmaceuticals NASDAQ:CRBP$14.83 +1.82 (+13.99%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$14.89 +0.06 (+0.43%) As of 10/3/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.Cybin NYSE:CYBN$6.08 -0.13 (-2.09%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$6.12 +0.04 (+0.74%) As of 10/3/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.Mersana Therapeutics NASDAQ:MRSN$8.28 +0.28 (+3.50%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$8.22 -0.06 (-0.72%) As of 10/3/2025 06:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Cheap Chipotle? Why CMG Stock Could Be Ready for a Comeback Alphabet: After Its Best Quarter in Decades, Is It Time to Buy? After Trump Deal, Can Meta Stock Withstand TikTok’s Onslaught? Starbucks Stock Slumps; This Competitor Shows Strength How Berkshire's OxyChem Buy Cements Its Long-Term Strength The Trade Desk: 2 Signs of a Comeback, 1 Risk Ahead NVIDIA Breaks Out to New Highs: What Comes Next? Down 22% From Highs, ServiceNow Could Be Too Cheap to Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
